Botulinum toxin type B

Botulinum toxin type B is a medically relevant serotype with a smaller product footprint than type A. Its current U.S. role is easiest to understand through Myobloc / Neurobloc, where Myobloc functions as a focused therapeutic type B reference rather than as a broad aesthetic peer to the major type A brands.

Product And Label Context

Myobloc is the U.S. brand name for rimabotulinumtoxinB; Neurobloc is the related name used in some non-U.S. contexts. Supernus Pharmaceuticals lists Myobloc in its current commercial portfolio (Supernus 🔗). Current U.S. prescribing information labels Myobloc for cervical dystonia and chronic sialorrhea in adults (DailyMed 🔗).

The focused footprint should not be mistaken for irrelevance. Type B defines an important boundary between serotype biology, product labeling, unit systems, treatment history, and practical treatment selection.

Mechanism Context

Type B reaches the same broad endpoint as other botulinum toxins: reduced release of selected nerve signals. The important biologic distinction is its intracellular target. Type B acts on synaptobrevin, also called VAMP, which is part of the SNARE machinery involved in signal release from nerve endings.

Botulinum toxin type A acts on a different SNARE protein, SNAP-25. That difference does not create a simple ranking, but it does matter when readers interpret serotype comparison, immunogenicity discussion, and product-specific clinical evidence.

Therapeutic Role

Type B is most visible in selected therapeutic settings rather than broad aesthetic practice. Myobloc’s U.S. label includes cervical dystonia and chronic sialorrhea in adults, while broader type B discussion may also involve prior response to type A treatment, tolerability, patient history, and local availability.

Those discussions still remain product-specific. A type B unit is not a type A unit under another name, and type B’s different serotype does not by itself answer questions about duration, tolerability, spread, or suitability for a particular patient.

Comparison With Type A

Type A is more visible because it has more marketed products, broader aesthetic presence, and wider indication coverage in the current market and literature. Type B is more specialized. The comparison is therefore about mechanism, label context, unit interpretation, treatment history, tolerability, and indication fit rather than about which serotype is generally better.

For a side-by-side comparison, see botulinum toxin type A vs type B. For response durability and antibody discussion, see botulinum toxin immunogenicity.